Introduction
The knowledge of extrahepatic metabolism in drug disposition is important. Extrahepatic drug metabolism can modify the systemic as well as tissue exposure of drug/metabolites and this becomes especially important in cases of active metabolite formation and certain disease states. For example, in severe cirrhosis of the liver, extrahepatic metabolic pathways might compensate for the impaired hepatic elimination of a drug (Patwardhan et al., 1981) . Tissue levels of drug/active metabolites might change depending upon the site of metabolism. For example, in case of irinotecan, its active metabolite SN-38 is conjugated to SN-38 glucuronide in liver, which is eliminated in the bile and metabolized by gut β -glucuronidase to regenerate SN-38. Locally formed SN-38 is thought to cause diarrhea (Araki et al., 1993; Takasuna et al., 1996; Michael et al., 2004) . Thus, information about sites of metabolism is important for appropriately selecting dosage , 1993) . It has been shown that phenolic compounds e.g. harmol (Mulder et al., 1984) and phenol (Cassidy and Houston, 1984) undergo pulmonary metabolism.
Trans-resveratrol (RES) is a dietary phytochemical known to have beneficial health effects via numerous mechanisms (Baur and Sinclair, 2006) . RES has been shown to induce apoptosis in human lung adenocarcinoma cells (Alex et al., 2010; Zhang et al., 2011; Zhang et al., 2012b) . It has been also shown to have lung cancer chemopreventive activity by altering the expression of genes involved in the phase I metabolism of polycyclic hydrocarbons (Mollerup et al., 2001) . Although the role of gut and liver is well known in the metabolism of RES (Kuhnle et al., 2000; Miksits et al., 2005; Brill et al., 2006; Iwuchukwu and Nagar, 2008; van de Wetering et al., 2009) , the role of lungs has not been evaluated in the metabolism of RES. RES is known to be extensively metabolized into its two major metabolites i.e. trans-resveratrol-3-sulfate (R3S) and trans-resveratrol-3-glucuronide (R3G) (Figure 1 ) in humans as well as rodents (Yu et al., 2002; Meng et al., 2004; Hoshino et al., 2010; Sharan et al., 2012) . A monosulfated metabolite of RES, R3S has recently been shown to be biologically active in in vitro studies (Hoshino et al., 2010) . Although glucuronides have generally been assumed to be pharmacologically inactive, examples do exist of active glucuronidated metabolites (Osborne et al., 1988; Kroemer and Klotz, 1992; Sperker et al., 1997) . No biological activity of R3G has been reported to date.
In our previous study with intra-arterial (i.a.) administration of RES , we observed that murine systemic clearance of RES was higher than hepatic blood flow, This article has not been copyedited and formatted. The final version may differ from this version. indicating the possibility of extrahepatic conjugation in the mouse. These results led us to investigate the lung as a possible metabolizing organ for RES. We studied the contribution of pulmonary metabolism of RES in vivo by using multiple sites of administration and a single site of sampling (Cassidy and Houston, 1980) , which exploits the anatomical arrangement of lungs. When administered i.v., RES enters the right atrium of the heart and crosses the lungs in a relatively undiluted form prior to reaching the general arterial system for distribution throughout the body. In contrast, when given i.a.
into the right carotid artery, RES is available immediately for tissue distribution. By comparison of plasma concentration time profiles following administration of RES by both routes, we calculated the contribution of lungs in the first pass metabolism of RES across the lungs. In vivo findings in mouse were further confirmed by in vitro experiments using lung fractions of mouse. Finally, in vitro studies using human lung fractions were also performed to compare mouse versus human RES pulmonary conjugation.
Materials and Methods:
This article has not been copyedited and formatted. The final version may differ from this version. Drug administration and blood sampling: RES was solubilized in 20% 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) in saline (Juan et al., 2010b . For human lung glucuronidation assay, the incubation was performed at 0.1, 0.5 and 2.5 mg/mL (final concentration) of human lung microsomes with substrate RES (0.5 mM)
solubilized in HP-β-CD (final HP-β-CD concentration 2%). Preliminary studies showed minimal glucuronidation in human lung microsomes, hence kinetic assays were not conducted.
In vitro pulmonary sulfation: RES sulfation activity was determined in pooled mouse lung S9 fraction and in pooled human lung S9 fraction. Conditions of protein and time linearity were optimized in preliminary studies. Preliminary experiments showed that the reactions were linear up to 60 min and 2.5 mg/mL of total protein for each protein source.
The incubation mixture consisted of mouse lung S9 fraction (final concentration, 1 mg/mL) or, human lung S9 fraction (final concentration, 0.5 mg/mL), the substrate RES 
LC-MS/MS Analysis:
RES, R3S and R3G concentrations in plasma and in the in vitro reaction mixture were measured with an electrospray ionization liquid chromatographytandem mass spectrometry system (ABSciex API 4000) set in negative ion scan mode as described previously . In brief, ascorbic acid (2.5 µL of a 15% solution) was added to 10 µL plasma samples and vortexed for 1 min. Agilent Technologies) and a gradient mobile phase of A 5mM ammonium acetate and B methanol. The elution started with 90% A at 0 min to 80% at 2 min, 65% at 10 min, 40%
at 12 min to 17 min and 90% at 19 min. Flow rate of the mobile phase was 1mL/min and the flow from the column was split 1:3 into an ABSciex API4000 triple quadrupole mass spectrometer equipped with a Turbo Ionspray source operating at 450°C. The column temperature was maintained at 35°C. The column effluent was monitored at the following precursor-product ion transitions: m/z 227→185 for RES, m/z 150→107 for IS (APAP), 403→113 for R3G and 307→227 for R3S with a dwell time of 400 ms for each ion transition. The retention time was ~ 5 min for IS (APAP), ~ 5.9min for R3G, ~ 9.2 min for R3S and ~ 14.2 min for RES. The lower limit of quantification was 2.4 ng/mL for R3S and 10 ng/mL for R3G and RES.
Noncompartmental pharmacokinetic analysis:
Pharmacokinetic parameters of RES, R3G and R3S were analyzed by noncompartmental analysis with Phoenix, WinNonlin (version 6.1, Pharsight Corporation, Palo Alto, CA).
The area under the plasma concentration-time curve (AUC) was calculated with the linear trapezoidal method; clearance (CL) was calculated as CL = Dose/AUC 0-inf ; volume of distribution at steady state (Vss) was calculated as Vss = CL×MRT 0-inf ; the terminal half- Michaelis-Menten parameter estimates were determined (Segel, 1993) .
Where v is the rate of the reaction, Vmax is the maximum velocity estimate, [S] is the substrate concentration, and Km is the Michaelis-Menten constant.
The following equation (equation 3) was used to fit the data exhibiting partial substrate inhibition profile (Hutzler and Tracy, 2002; Tracy and Hummel, 2004) :
where Ki is the partial substrate inhibition constant. Nonlinear regression was performed with GraphPad Prism for Windows (version 4.03; GraphPad Software Inc., San Diego, CA).
Statistics: Student's unpaired t test was used, with p < 0.05 set as the significance level.
GraphPad Prism for Windows (version 4.03; GraphPad Software Inc., Sand Diego, CA) was used to perform statistical analysis.
This article has not been copyedited and formatted. The final version may differ from this version. In vitro pulmonary metabolism: The glucuronidation of RES was studied in mouse and human lung fractions. Figure 3A shows the formation rate of R3G in mouse lung fraction with its Eadie-Hofstee (E-H) plot shown as inset. The R3G profile exhibited partial substrate inhibition. This was determined by fitting the data to the partial substrate inhibition equation
(equation 3) and by visual examination of E-H plot. The E-H plot showed a hook in the upper quadrant typical of partial substrate inhibition kinetic profile ( Figure 3A inset) (Hutzler and Tracy, 2002) . Enzyme kinetic parameters are presented in Table 2 . When RES was incubated with 0.1 and 0.5 mg/mL human lung microsomes, no R3G was observed above LOQ (10 ng/mL for R3G) at the end of 60 min incubation. Therefore no further RES glucuronidation kinetic studies were performed with human lung microsomes. Figure 3B and 3C show the formation kinetics of R3S in mouse and human lung fractions with Eadie-Hofstee (E-H) plots as insets respectively. R3S formation in both mouse and human lung fractions showed partial substrate inhibition (Hutzler and Tracy, 2002) .
This article has not been copyedited and formatted. The final version may differ from this version. RES is known to be extensively metabolized into its conjugates, mainly R3G and R3S (Yu et al., 2002; Meng et al., 2004; Hoshino et al., 2010; Iwuchukwu et al., 2012) ).
Lungs are the third in a series of three potential biotransformation sites (along with the gut and liver) which orally ingested RES must cross before entering the general circulation. at its 3-OH position via UGT1A1, UGT1A7, and UGT1A9, with minor contribution from UGT1A8, UGT1A10 and UGT2B7 (Brill et al., 2006) . Ugt1a6 has been shown to be expressed well in mouse lung (Buckley and Klaassen, 2007) , and might be responsible for RES glucuronidation in mouse lungs. There are conflicting reports about the presence of UGT enzymes in human lung. UGT1A1 and UGT1A10 have been reported in lung cancer samples (Oguri et al., 2004) . Several UGT2B isozymes are reportedly present in human lungs (Turgeon et al., 2001) . UGT expression as well as activity has been reported in the upper respiratory tract but not in lungs in humans (Zheng et al., 2002) , which becomes important for inhaled compounds. Other studies have shown low or no UGT expression in normal human lung tissue (Zheng et al., 2002; Somers et al., 2007; Nakamura et al., 2008) . In the present study, the absence of R3G formation in human lung fraction is consistent with low or absent expression of UGT isoforms in normal human lung tissue (Nakamura et al., 2008) 18 lungs might be responsible for R3S formation. Steroid sulfatase activity has been reported in human (Milewich et al., 1983) and mouse lung tissue (Milewich et al., 1984) , with highest activity in microsomal fraction of human lung tissue homogenate (Milewich et al., 1983) . Steroid sulfatase can desulfate R3S to give RES locally in the lung cells.
This futile cycling of RES/R3S by the combined activity of sulfatase and sulfotransferase enzyme can lead to increase in the retention of the RES/R3S within the lung. This can be important since RES and R3S both have been shown to have pharmacological activity in vitro (Hoshino et al., 2010) . in rodents versus humans. In rodents R3G has been observed as the quantitatively major metabolite (Juan et al., 2010b; Colom et al., 2011; Iwuchukwu et al., 2012; Sharan et al., 2012 ) as compared to R3S in humans (Boocock et al., 2007; Brown et al., 2010 
